학술논문

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Document Type
Article
Source
In: The Lancet HIV. (The Lancet HIV, June 2019, 6(6):e355-e363)
Subject
Language
English
ISSN
23523018